Exterior of Astellas’ United States office, where teams develop innovative therapies with integrity and patient-first focus.

United States newsroom

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.

Month Year

Month Year

Jan 27, 2005

Data from Phase III Study Show Tarceva Plus Gemcitabine Significantly Improves Survival Compared to Gemcitabine Alone in Advanced Pancreatic Cancer Patients

Tarceva is the Only Epidermal Growth Factor Receptor (EGFR) Therapy to Show an Improvement in Survival in Pancreatic Cancer HOLLYWOOD, Fla.--(BUSINESS WIRE)--Jan. 27, 2005--OSI Pharmaceuticals,...

Read more about Data from Phase III Study Show Tarceva Plus Gemcitabine Significantly Improves Survival Compared to Gemcitabine Alone in Advanced Pancreatic Cancer Patients

Show per page

Discover more

Return to global media homepage

U.S.

Follow U.S. news

Subscribe to news alerts